BACKGROUND	To determine the dosage requirements and pharmacokinetics of atevirdine , a non-nucleoside reverse transcriptase inhibitor and its N-dealkylated metabolite ( N-ATV ) during phase I studies in patients receiving atevirdine alone or in combination with zidovudine .\